ORIGINAL RESEARCH article
Front. Neurol.
Sec. Dementia and Neurodegenerative Diseases
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1588992
Reliable Monitoring of Respiratory Function with Home Spirometry in People Living with Amyotrophic Lateral Sclerosis
Provisionally accepted- 1EverythingALS, Seattle, California, United States
- 2Universidad de Buenos Aires, Facultad de Ciencias Exactas y Naturales, Departamento de Física., Buenos Aires, Argentina
- 3CONICET - Universidad de Buenos Aires, Instituto de Física Interdisciplinaria y Aplicada (INFINA), Buenos Aires, Argentina
- 4SRI International, Menlo Park, California, United States
- 5Bristol Myers Squibb, Cambridge, United States
- 6Department of Neurology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States
- 7Department of Medicine, MCG-Hearst Health, Drexel University College of Medicine, Philadelphia, United States
- 8Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
- 9Eli Lilly and Company, Boston, United States
- 10Department of Biological Engineering, School of Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States
- 11Sean M. Healey and AMG Center for ALS, Massachusetts General Hospital & Harvard Medical Schoo, Boston, United States
- 12Escuela de Ciencia y Tecnología, Universidad Nacional de General San Martín, Buenos Aires, Buenos Aires, Argentina
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Monitoring respiratory function is essential for assessing the progression of Amyotrophic Lateral Sclerosis (ALS) and planning interventions. Using spirometry data from the Radcliff Study (a fully remote, longitudinal, exploratory study with a cohort of 67 pALS) we demonstrate that flexible coaching, combined with a quality control analysis that excludes values of `0' and timepoints with failed measurement trials, produces consistent remote spirometry results. Our findings indicate that home-measured Slow Vital Capacity (SVC) and Forced Vital Capacity (FVC) evolve similarly and progress linearly over the study period (7.7 ± months). This remains true in both slow and fast progressor subpopulations. This observed linearity in respiratory trajectories supports the potential for early, accurate estimation of progression, reinforcing the feasibility of less frequent monitoring without compromising assessment precision, and reducing the burden on both pALS and the healthcare system. Furthermore, our results align with reported in-clinic pulmonary tests, validating remote monitoring as a means to promote more equitable and accessible clinical trial designs.
Keywords: Home spirometry, Amyotrofic Lateral Sclerosis (ALS), pulmonary function test, Proctoring, Telemedicine
Received: 06 Mar 2025; Accepted: 26 May 2025.
Copyright: © 2025 Peller, Trevisan, Bujia, Aguirre, Shalom, Taitz, Henze, Bastola, Osik, Shewcraft, Jiang, Schwartz, Heiman-Patterson, Sherman, Wipperman, Levy, Shou, Sillay, Ostrow, Fraenkel, Berry, Navar Bingham and Roitberg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Julian Peller, EverythingALS, Seattle, California, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.